EUVIMEDEUVIMED entdecken
Open Access

Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act

Harry Doernberg, Joshua D Wallach, Molly M Jeffery, Maryam Mooghali, Reshma Ramachandran, Joseph S Ross

JAMA Internal Medicine · 01.02.2026 · 186 (2) · 233

DOI: 10.1001/jamainternmed.2025.6566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.02.2026. Verfasst von Harry Doernberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Product Surveillance, Postmarketing, Drug Approval, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The 2007 US Food and Drug Administration (FDA) Amendments Act (FDAAA) expanded its safety-related regulatory authorities, including enhanced postmarketing safety surveillance and new clinical study requirements. However, whether FDAAA has been associated with differences in the frequency and timing of postmarket safety-related actions remains poorly understood.

Objectives

To assess whether FDAAA was associated with differences in time to first FDA postmarket drug safety−related action, and to assess whether therapeutic and regulatory characteristics were associated with differences in time to these actions post-FDAAA implementation. Design and Setting This was a cross-sectional study of all novel therapeutics approved by FDA between January 1, 2001, and December 31, 2019, and followed up through December 31, 2024. Approvals were categorized as pre- or post-FDAAA (before or after March 25, 2008). Post-FDAAA therapeutic and regulatory characteristics included drug class, therapeutic area, orphan status, special regulatory pathway, and presence of a boxed warning or FDAAA-mandated postmarket study requirement at approval. Main Outcomes and Measures Time to first FDA postmarket drug safety−related action, a composite of withdrawals due to safety concerns, incremental boxed warnings, and safety-related communications.

Results

Of the 560 novel therapeutics approved, FDA took postmarket safety-related actions for 130 (23.2%) during a median (IQR) follow-up of 12.1 (7.8-18.2) years. These comprised actions within 5 years of approval for 34 of 164 therapeutics (20.7%) approved pre-FDAAA, and 57 of 396 (14.4%) approved post-FDAAA (rate ratio, 0.69; 95% CI, 0.47-1.02; P = .06). Compared to pre-FDAAA approvals, after accounting for therapeutic and regulatory characteristics, there was no statistically significant difference in time to first postmarket safety-related action for post-FDAAA approvals (time ratio, 0.40; 95% CI, 0.15-1.07; P = .07). However, among therapeutics with postmarket safety-related actions within 5 years of approval, median time to first action was shorter post-FDAAA (median [IQR], 3.1 (2.0-4.2) years for pre-FDAAA vs 1.8 [1.3-2.5] years post-FDAAA; P = .004). Among 260 novel therapeutics approved post-FDAAA, after the October 2013 enactment of breakthrough therapy designation, the following therapeutic and regulatory characteristics were associated with time to first postmarket safety-related action: small molecule type (time ratio, 0.24; 95% CI, 0.07-0.81; P = .02), orphan designation (time ratio, 8.29; 95% CI, 2.43-28.27; P < .001), fast track (time ratio, 0.22; 95% CI, 0.08-0.64; P = .005), breakthrough therapy designation (time ratio, 0.10; 95% CI, 0.03-0.32; P < .001), prolonged regulatory review time (>400 days; time ratio, 0.16; 95% CI, 0.03-0.73; P = .02), and FDAAA-mandated postmarket study requirements at approval (time ratio, 0.35; 95% CI, 0.15-0.80; P = .01). Conclusions and Relevance This cross-sectional analysis found that the enhanced safety-related regulatory authorities of FDAAA were not associated with differences in time to first postmarket safety-related action. However, among therapeutics with postmarket safety-related actions within 5 years of approval, median time to first action was shorter post-FDAAA implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationProduct Surveillance, PostmarketingDrug ApprovalDrug-Related Side Effects and Adverse ReactionsUnited StatesHumansCross-Sectional StudiesTime Factors

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, Connecticut.
  • Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia.
  • Division of Health Care Delivery Research, Mayo Clinic, Rochester, Minnesota.
  • Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota.
  • Section of General Medicine and the Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
  • Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.

Zitieren

APA

Doernberg, H., Wallach, J. D., Jeffery, M. M., Mooghali, M., Ramachandran, R., & Ross, J. S. (2026). Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act. JAMA Internal Medicine, 186(2), 233. https://doi.org/10.1001/jamainternmed.2025.6566

Vancouver

Doernberg H, Wallach JD, Jeffery MM, Mooghali M, Ramachandran R, Ross JS. Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act. JAMA Internal Medicine. 2026;186(2):233. doi:10.1001/jamainternmed.2025.6566

BibTeX
@article{Doernberg2026,
  author = {Doernberg, Harry and Wallach, Joshua D and Jeffery, Molly M and Mooghali, Maryam and Ramachandran, Reshma and Ross, Joseph S},
  title = {Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {2},
  pages = {233},
  doi = {10.1001/jamainternmed.2025.6566}
}
Kostenlos starten →